Blog

On November 30th 2022, the Food and Drug Administration in the U.S. approved a new kind of drug: a fecal microbiota product for treating antibiotic-resistant C. difficile infection[1]. In the near future, similar treatments derived from fecal bacteria and metabolites could help treat drug-resistant cancer.

Dr. Charlene Mantia, a medical oncologist at Dana-Farber Cancer Institute specialized in cancers of the genitourinary tract, presented and discussed bladder cancer clinical updates from the ESMO 2022. “There is not a lot of practice-changing in bladder cancer, but there are the important updates from the EV-103 Cohort K”, dr. Mantia started.

Dr. Vincent Xu, a genitourinary oncologist at the Dana-Farber Cancer Institute in Boston, Massachusetts, presented and discussed the kidney cancer clinical updates from the ESMO 2022 which he described as a “huge conference for kidney cancer”.

According to the results of the phase IIb KEYNOTE-942 trial, the combination of mRNA-4157/V940 and KEYTRUDA® significantly reduces the risk of disease recurrence or death in stage III/IV melanoma patients with a high risk of recurrence following complete resection compared to KEYTRUDA® monotherapy.[1] These findings represent the first evidence of the efficacy of an investigational mRNA cancer treatment in a randomised clinical trial.